ALLMedicine™ Meningioma Center
Research & Reviews 2,192 results
https://clinicaltrials.gov/ct2/show/NCT04305470
Oct 21st, 2021 - This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic performance, and clinical usefulness of the imaging agent Gleolan™ (Aminolevulinic Acid Hydrochloride, ALA HCl, ALA, 5-ALA), an orally administered imaging ...
https://doi.org/10.1136/bcr-2021-245249
BMJ Case Reports; Konnakkaparambil Ramakrishnan K, Mohan L et. al.
Oct 21st, 2021 - Central nervous system tumours can occasionally present with psychiatric symptoms as the only manifestation and can often pose diagnostic challenges. A man in his early 60s presented to the psychiatry outpatient department with delusional parasito...
https://doi.org/10.1158/1055-9965.EPI-21-0797
Cancer Epidemiology, Biomarkers & Prevention : a Publicat... Radkiewicz C, Järkvik Krönmark J et. al.
Oct 20th, 2021 - Advanced age is a consistent risk factor for cancer, nonetheless cancer incidence typically declines after age 75-85 for most solid tumors. To delineate the true cancer age-incidence pattern, we performed a population-based cohort study using Swed...
https://doi.org/10.1007/s11060-021-03865-w 10.1055/s-0039-1687892 10.1097/moh.0000000000000072 10.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E 10.3390/cancers12061354 10.3171/2018.7.Jns181175 10.3171/jns.2007.106.4.601 10.1182/asheducation-2016.1.196 10.1007/s11060-009-9886-4 10.1007/s11060-018-2810-z 10.1371/journal.pone.0079170 10.1016/j.clineuro.2020.106460 10.1016/j.clineuro.2014.06.001 10.3171/2010.6.Jns091974 10.1002/14651858.CD008500.pub3 10.1182/blood-2017-02-767285 10.1055/s-0039-1688493 10.1016/j.ctrv.2021.102190 10.1182/bloodadvances.2020003442 10.5482/hamo-14-08-0037 10.1016/j.thromres.2011.12.022 10.1182/blood-2013-04-460139 10.1615/CritRevOncog.2018024859 10.1111/jth.14130 10.1016/j.thromres.2018.01.036 10.1182/blood-2007-10-116327 10.1016/s0049-3848(14)50007-2 10.1016/s2352-3026(18)30063-2 10.1002/ajh.24700 10.1016/j.thromres.2020.09.005 10.1200/jco.2010.32.8294 10.1093/neuonc/nou106 10.1007/s11060-010-0290-x 10.1371/journal.pone.0069034 10.1002/cyto.b.20551 10.1007/s11239-021-02441-3 10.1055/s-2006-939555 10.1016/s0049-3848(10)70005-0 10.1016/j.thromres.2010.09.002 10.1055/s-0037-1613868 10.1111/j.1538-7836.2005.01511.x 10.5137/1019-5149.Jtn.22739-18.3 10.1055/s-0033-1357483 10.1016/j.wneu.2018.09.177 10.1055/s-2002-20561 10.1160/th12-12-0957 10.3390/biom11050663 10.1016/s0049-3848(20)30405-9 10.1007/s11060-010-0462-8 10.1016/j.thromres.2012.09.020 10.1016/j.critrevonc.2017.08.003 10.1093/neuonc/now187 10.7326/0003-4819-149-5-200809020-00010
Journal of Neuro-oncology; Yerrabothala S, Gourley BL et. al.
Oct 16th, 2021 - Up to 30% of patients with glioblastoma (GBM) develop venous thromboembolism (VTE) over the course of the disease. Although not as high, the risk for VTE is also increased in patients with meningioma. Direct measurement of peak thrombin generation...
https://doi.org/10.1093/ije/dyab140
International Journal of Epidemiology; Auvinen A, Cardis E et. al.
Oct 15th, 2021 - Exposure to high doses of ionizing radiation is among the few well-established brain tumour risk factors. We used data from the Interphone study to evaluate the effects of exposure to low-dose radiation from diagnostic radiological examinations on...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566438
Neurosurgery Marchetti M, Sahgal A et. al.
May 29th, 2020 - Stereotactic radiosurgery (SRS) for benign intracranial meningiomas is an established treatment. To summarize the literature and provide evidence-based practice guidelines on behalf of the International Stereotactic Radiosurgery Society (ISRS). Ar...
Clinicaltrials.gov 16 results
https://clinicaltrials.gov/ct2/show/NCT04305470
Oct 21st, 2021 - This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic performance, and clinical usefulness of the imaging agent Gleolan™ (Aminolevulinic Acid Hydrochloride, ALA HCl, ALA, 5-ALA), an orally administered imaging ...
https://clinicaltrials.gov/ct2/show/NCT02933736
Oct 11th, 2021 - 900 mg/d is the maximally tolerated dose (MTD), as determined in a recent Novartis-sponsored Phase I study for advanced solid tumor patients. The recommended dose expansion and Phase 2 is 600mg/d for 3 weeks on and 1 week off. Due to drug pharmaco...
https://clinicaltrials.gov/ct2/show/NCT04081701
Oct 4th, 2021 - To date, the utility of Ga-68-DOTATATE PET/MRI in meningioma has not been explored. Investigators have over the past 3 months been able to accrue the largest case series of presently 12 patients in whom Ga-68 DOTATATE PET/MRI demonstrated utility ...
https://clinicaltrials.gov/ct2/show/NCT05023018
Aug 26th, 2021 - This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma followi...
https://clinicaltrials.gov/ct2/show/NCT04997317
Aug 9th, 2021 - The somatostatin receptor subtype 2 (sstr2) has been identifies as a peptide hormone receptor that is highly expressed in 70 - 100% of meningiomas representing an attractive target for so called "theranostic" applications combining molecular imagi...
News 31 results
https://www.onclive.com/view/novel-treatments-in-glioblastoma-looking-ahead
Apr 2nd, 2021 - Transcript:Steven A. Toms, MD: What is the future of a device like Optune? It seems to be a fairly basic mechanism in cancer that may be used in other areas. Certainly, I know that there are trials going on in Europe right now for lung, ovarian, a...
https://www.medscape.com/viewarticle/945218
Feb 3rd, 2021 - New details confirm an increased risk of developing intracranial meningiomas after prolonged use of the hormonal product cyproterone acetate. Cyproterone acetate is a synthetic progestogen and potent anti-androgen that has been used in the treatme...
https://www.onclive.com/view/nyeso1-gains-momentum-as-a-therapeutic-target
Dec 5th, 2020 - As the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies. Promising results have been obtained from early studies, prompting the rapid expansion of the f...
https://www.mdedge.com/dermatology/article/225971/pediatrics/atretic-cephalocele-hypertrichosis
Jameson T. Loyal, MD, Emily Farrell, MD et. al.
Jul 23rd, 2020 - To the Editor: A 2-week-old female infant presented to our dermatology clinic for evaluation of a 4. 0×4.
https://www.medscape.com/viewarticle/925271
Feb 14th, 2020 - Cyproterone products with daily doses of 10 mg or more should be restricted because of a risk of developing meningioma, says the safety committee of the European Medicines Agency. Products containing cyproterone 10 mg daily or more should be used ...
